UNSPSC 51112527: Sarcolysin hydrochloride

This classification denotes a nitrogen mustard compound with the molecular formula C13H18Cl2N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GEG3Q4FC64, chemically known as alanine, 3-(p-(bis(2-chloroethyl)amino)phenyl)-, monohydrochloride, dl-, but more generally known as sarcolysin hydrochloride, which bears US NIH Compound Identifier 4053. European Medicines Agency schedules sarcolysin hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10448MIG.

Most nations, for tariff purposes, schedule sarcolysin hydrochloride under HS 29224995. SMILES: C1CC(CCC1CC(C(=O)O)N)N(CCCL)CCCL.CL.

UNSPSC 51112527 Sarcolysin hydrochloride is a Commodity code covering a specific pharmaceutical product. State and local governments procure sarcolysin hydrochloride primarily through health and human services agencies managing pharmacy benefit programs and medication access for state employee and retiree populations. The recent procurement activity under this code reflects broader state interest in direct-to-manufacturer pharmaceutical sourcing models that bypass traditional pharmacy benefit managers and group purchasing organizations, aimed at improving cost management and prescription fulfillment efficiency. Health and human services commissions issuing under this code typically structure solicitations as exploratory requests for information or formal RFPs that solicit vendor capacity to negotiate net-pricing pharmaceutical contracts, implement outcomes-based payment arrangements, and manage high-volume prescription fulfillment for self-insured state employee health plans.

The Texas Health and Human Services Commission posted Request for Information HHS0017013 on April 3, 2026, seeking vendor capabilities and market intelligence for its Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI solicited detailed vendor responses regarding direct contracting experience with self-insured employers and government health plans, flexibility to negotiate net-pricing models without traditional rebate structures, and capacity to implement value-based or outcomes-based agreements. The commission did not disclose an award value, budget range, or formal evaluation timeline as part of this preliminary information-gathering phase, indicating that Texas HHS intends to use vendor responses to develop detailed procurement specifications and implementation terms before issuing a formal competitive solicitation.